Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - ...

Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithing...

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a ...

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and ex...

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports...

Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for which it expects to receive gross proceeds of approxi...

Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial year...

Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has b...

12:05pm: US markets trend downward US stocks continued to plummet midday on Tuesday, as investors eyed earnings reports from some major corporates and fretted over looming interest rate rises. At noon...

Orgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (P...

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.

Orgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.”   The...

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a l...

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform.  The global biotech company, which is foc...

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platf...

Orgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement...

Orgenesis Inc said its 2Q 2021 revenues rose from $1.75 million to $10.5 million compared to the same period in 2020.  The international biotech company, which is focused on unlocking the full potenti...